08.00.41c, Teprotumumab-trbw (Tepezza®)
Independence Blue Cross added three new ICD-10 diagnosis codes (H05.831, H05.832, H05.833) for thyroid orbitopathy to policy 08.00.41c effective 10/01/2025. This is a coding update only; the coverage criteria, dosing, and medical necessity requirements for Tepezza remain unchanged. Billing teams must ensure these new codes are available in their systems and used appropriately when submitting claims for thyroid eye disease.